CSPG4 and melanoma: In 2019, the optimized protocol was used in producing genetically modified CAR T-cells against melanomas; the CAR T-cells were electroporated and expanded with mRNA that encoded CAR targeting CSPG4, a surface protein highly expressed in most melanomas.